San Diego-primarily based Viking Therapeutics marked itself as a significant competitor from the weight loss drug current market in February following revealing promising details from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection and in March t